Ravi Chari, Ph.D.
Affiliations: | 2006 | University of Connecticut, Storrs, CT, United States |
Area:
Pharmaceutical Chemistry, General BiophysicsGoogle:
"Ravi Chari"Mean distance: (not calculated yet)
Parents
Sign in to add mentorAlexandros Makriyannis | grad student | 2006 | University of Connecticut | |
(A study of the conformational and pharmacophoric requirements of ligands of the cannabinergic system using NMR and computer modeling.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Ponte JF, Lanieri L, Khera E, et al. (2020) Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody Drug Conjugates to Increase In Vivo Efficacy. Molecular Cancer Therapeutics |
Bai C, Reid E, Wilhelm A, et al. (2019) Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. Bioconjugate Chemistry |
Costoplus JA, Veale KH, Qiu Q, et al. (2019) Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing. Acs Medicinal Chemistry Letters. 10: 1393-1399 |
Archer KE, Reid EE, Shizuka M, et al. (2019) Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs). Acs Medicinal Chemistry Letters. 10: 1211-1215 |
Lau J, Salomon P, Sinkevicius K, et al. (2019) Abstract 538: LC-MS based catabolite identification study of an ADC with DM21-C, a novel maytansinoid linker-payload Cancer Research. 79: 538-538 |
Wu R, Gavrilescu C, Liu Y, et al. (2018) Abstract 2900: Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates Cancer Research. 78: 2900-2900 |
Sun X, Ponte JF, Yoder N, et al. (2017) Effects of Drug-Antibody Ratio (DAR) on Pharmacokinetics, Biodistribution, Efficacy and Tolerability of Antibody-Maytansinoid Conjugates. Bioconjugate Chemistry |
Qiu Q, Wu R, Lanieri L, et al. (2017) Abstract 71: Bystander activity andin vivoefficacy of a folate receptor α (FRα)-targeting antibody-drug conjugate with a novel peptide linker Cancer Research. 77: 71-71 |
Chari RV. (2016) Expanding the Reach of Antibody-Drug Conjugates. Acs Medicinal Chemistry Letters. 7: 974-976 |
Miller ML, Fishkin NE, Li W, et al. (2016) A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity. Molecular Cancer Therapeutics |